Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumabHelèn Heyerdahl, Jostein Dahle, Nasir Abbas et al.|PLoS ONE|2012Cited by 63
Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumabNasir Abbas, Jostein Dahle, Jahn Nesland et al.|EJNMMI Research|2011Cited by 57
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximabJostein Dahle, Roy H. Larsen, Anne Kristine Hjelmerud et al.|European Journal of Nuclear Medicine and Molecular Imaging|2009Cited by 43
Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-TrastuzumabHelèn Heyerdahl, Jostein Dahle, Åsmund Larsen et al.|International Journal of Radiation Oncology*Biology*Physics|2011Cited by 42
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003Astri Fjelde Maaland, Jostein Dahle, Amal Saidi et al.|PLoS ONE|2020Cited by 39